MedTrace Logo

Primary Hepatobiliary Cancer Cohort of Central China

NCT05520801 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2023-12-19

No results posted yet for this study

Summary

This registry is designed as a longitudinal cohort study of patients diagnosed with primary hepatobiliary cancer in Tongji Hospital, Wuhan. This study collects the clinical-pathological features of hepatic malignant tumors and the current status of patients who received comprehensive treatment based on surgical treatment since 1998.

Conditions

Sponsors & Collaborators

  • Chinese Cooperative Group of Liver Cancer

    collaborator OTHER

  • Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province

    collaborator OTHER

  • Haplox Biotechnology Co., Ltd.

    collaborator INDUSTRY

  • Geneplus-Beijing Co. Ltd.

    collaborator INDUSTRY

  • YuceBio Technology

    collaborator UNKNOWN

  • Gelesis, Inc.

    collaborator INDUSTRY

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Bixiang Zhang · Tongji Hospital

  • Zeyang Ding · Tongji Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2024-12-31
Completion
2025-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05520801 on ClinicalTrials.gov